Cutting out the unnecessary: deprescribing antihypertensive treatments in patients at low cardiovascular risk

• by Matteo Lemoli, Claudia Agabiti Rosei, Maria Lorenza Muiesan

• February 10, 2026

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.

• by Kathryn Wighton

• May 27, 2026

• 5 min

VSMCs and the immune microenvironment: a multidimensional regulatory network driving vascular injury and repair

• by Yuxin Wei, Yuanpeng Liao, Cong Zhang, Jiawei Guo

• June 5, 2026

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

• by Kathryn Wighton

• June 11, 2026

• 2 min